Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     

  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     

  • Bitcoin GBP

    52,035.48
    +616.86 (+1.20%)
     

  • CMC Crypto 200

    1,334.09
    +21.46 (+1.64%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

STOCKS NEWS EUROPE--Carmat jumps on artificial heart approval

Reuters - UK Focus

Shares in Carmat soar 25 percent after the company receives the green light from French authorities to carry out the first human implants of its bioprosthetic artificial heart on four patients in three approved French hospitals.

Carmat, whose shareholders include European venture capital firm Truffle Capital (OTC BB: CGHC - news) and aerospace group EADS (Paris: NL0000235190 - news) , adds that it intends to start choosing patients immediately.

"This is very good news," Portzamparc analysts write. "(The French authorities) were the hardest to convince, their authorisation is proof of the quality of the work carried out."

Developed by a team of engineers from Airbus parent EADS, the Carmat devices mimic heart muscle contractions with two micro pumps, one for each ventricle or heart chamber.

To see a statement, please click

Reuters messaging rm://james.regan.thomsonreuters.com@reuters.net